Pfizer has introduced the firm’s Nivestym (filgrastim-aafi) biosimilar in the US, at the previously-promised “significant discount” to the current wholesale acquisition cost (WAC) of Amgen’s Neupogen original, and a double-digit reduction on the price of competing biosimilar and follow-on products.
Revealing that shipments to wholesalers had begun on 24 September, Pfizer announced that the biosimilar had been available since 1...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?